Ask AI

Setting New Standards With TROP2-Directed Therapy in NSCLC: Leveraging ADC Innovation to Meet Unmet Patient Needs

Enhance your understanding of current and investigational TROP2-directed ADCs used to treat patients with NSCLC to personalize therapy and improve clinical outcomes through a certified on-demand webcast, expert-written ClinicalThought commentary, podcast, certified interactive case challenges, and downloadable slides.

Share

Program Content

Activities

TROP2 Therapy in NSCLC
Setting New Standards With TROP2-Directed Therapy in NSCLC: Leveraging ADC Innovation to Meet Unmet Patient Needs
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 28, 2026

No activities added yet

Provided by

ProCE Banner
ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.